Evotec Extends Ongoing Collaboration with CHDI Foundation
News Nov 05, 2012
Evotec AG has announced that CHDI Foundation, Inc. (CHDI), a privately-funded not-for-profit research organization dedicated to developing therapies for Huntington's disease (HD), has extended its collaboration with Evotec until the end of 2015. This contract extension could be worth up to USD 41 million in research payments for Evotec.
The collaboration takes full advantage of Evotec's integrated drug discovery platform and its proficiency in neurological research, including its expertise in medicinal chemistry, in vitro and in vivo pharmacology, and compound management.
Evotec and CHDI entered into this alliance in March 2006, and since then the collaborative relationship has grown significantly. The extension of this collaboration further validates Evotec's broad expertise in CNS drug discovery and development.
'We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington's disease, continues to work in partnership with Evotec,' said Dr Mario Polywka, Chief Operating Officer of Evotec.
Dr Polywka continued, 'This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec's platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts.'
'CHDI partners with a global network of investigators from the academic, biopharmaceutical, and service sectors to execute our drug discovery and development efforts,' said Dr Robert Pacifici, Chief Scientific Officer at CHDI.
Dr Pacifici continued, 'Evotec represents one of our largest and longest standing relationships with a contract research organization. We are delighted that, with the renewal of our contract, CHDI and Evotec will be able to continue our productive interactions and drive our therapeutic programs forward.'
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE